The Study
Intranasal Human NSC‐Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS‐STING Signalling, in Aged Hippocampus
This study is like a fair science experiment in mice: they gave some mice a special treatment and others a placebo, then watched what happened. Because they randomly picked who got what and didn’t tell the scientists who was who, they can say the treatment probably caused the improvements—not just that they happened together.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists gave old mice tiny bubbles (called EVs) made from human stem cells through their nose. These bubbles carried special messages that told the brain's immune cells to calm down, fix damaged energy factories, and stop causing inflammation.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 517 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — improved memory in mice suggests this therapy could potentially help humans with age-related memory loss like early Alzheimer’s.
- 2Treated mice remembered new objects 30-50% better than untreated mice and explored new locations more often.
- 3Their brain inflammation markers dropped by 20-80%, and mitochondrial genes increased significantly.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Related Content
Claims (6)
Intranasal delivery of extracellular vesicles from stem cells reduces the activity of specific inflammatory pathways and lowers levels of key inflammatory proteins in the hippocampus of aged mice.
Administering extracellular vesicles derived from human stem cells through the nose to aged mice reduces inflammation in the hippocampus and improves cognitive performance by inhibiting specific molecular pathways involved in inflammatory responses.
When aged mice are treated with extracellular vesicles derived from human stem cells through the nose, there is a reduction in brain inflammation markers, lower levels of oxidative stress, increased activity of genes related to mitochondrial function, and improved performance in memory tests.
In older mice, a treatment using tiny particles derived from stem cells, delivered through the nose, reduces specific inflammatory structures in brain immune cells that are linked to neurodegenerative conditions.
In older mice, delivering extracellular vesicles from stem cells through the nose alters gene activity in brain immune cells, increasing expression of genes involved in energy production and stress defense while decreasing expression of genes linked to inflammation.
In older mice, a treatment using tiny particles derived from stem cells, delivered through the nose, leads to better performance in memory tests that measure the ability to recognize new objects and remember their locations.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.